Literature DB >> 16616848

Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP).

Jean-Benoit Arlet1, Dalia Dimitri, Christian Pagnoux, Olivier Boyer, Thierry Maisonobe, François-Jérome Authier, Coralie Bloch-Queyrat, Claire Goulvestre, Farhad Heshmati, Marielle Atassi, Loïc Guillevin, Serge Herson, Olivier Benveniste, Luc Mouthon.   

Abstract

We report two patients with myopathy associated with anti-signal recognition particle Ab, refractory to conventional therapy, who were treated with prednisone and plasma exchange, followed by rituximab. A marked response was observed in both patients, with partial to complete recovery of muscle strength, which was sustained.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16616848     DOI： 10.1016/j.nmd.2006.03.002

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN： 0960-8966            Impact factor:   4.296


  18 in total

1.  Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.

Authors:  Ritu Valiyil; Livia Casciola-Rosen; Grace Hong; Andrew Mammen; Lisa Christopher-Stine
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-09       Impact factor: 4.794

Review 2.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

Review 3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 4.  Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.

Authors:  Pari Basharat; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

Review 5.  Efficacy and safety of rituximab in rheumatic diseases.

Authors:  Eva Rath; Jochen Zwerina; Bastian Oppl; Valerie Nell-Duxneuner
Journal:  Wien Med Wochenschr       Date:  2015-01-21

Review 6.  Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Authors:  Leandro Ladislau; Louiza Arouche-Delaperche; Yves Allenbach; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2018-08-03       Impact factor: 4.592

7.  Immune-mediated necrotising myopathy associated with antibodies to the signal recognition particle treated with a combination of rituximab and cyclophosphamide.

Authors:  Marisa Fernandes das Neves; Joana Caetano; Susana Oliveira; José Delgado Alves
Journal:  BMJ Case Rep       Date:  2015-08-03

Review 8.  Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.

Authors:  Siamak Moghadam-Kia; Chester V Oddis; Rohit Aggarwal
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 9.  Myopathy associated with anti-signal recognition particle antibodies with pulmonary involvement and response to rituximab.

Authors:  Carolina Mazeda; Rita Cunha; Pedro Gonçalo Ferreira; Anabela Barcelos; Renata Aguiar
Journal:  Rheumatol Int       Date:  2021-06-04       Impact factor: 2.631

Review 10.  Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series.

Authors:  Anji Xiong; Guancui Yang; Zhuoyao Song; Chen Xiong; Deng Liu; Yu Shuai; Linqian He; Liangwen Zhang; Zepeng Guo; Shiquan Shuai
Journal:  Ther Adv Neurol Disord       Date:  2021-03-12       Impact factor: 6.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.